Cronin has worked at Moderna since 2021, when she was brought on to market the biotech company’s COVID-19 vaccine.

Citi analyst Geoff Meacham reiterated a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $40.00. The ...

The personalized cancer vaccine market is gaining rapid momentum, driven by biotech advancements and rising demand for targeted immunotherapies. The new 2025 report analyzes key players like BioNTech, ...

Contract Development and Manufacturing Organizations (CDMOs) enhance drug discovery by providing essential services that ...

In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), with a ...

National Institutes of Health officials have urged scientists to remove all references to mRNA vaccine technology from their ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...

Shares of clinical-stage biotech Chimerix skyrocketed following an acquisition agreement from Jazz Pharmaceuticals for ... Shares of Moderna gained after a couple of SEC filings showed that ...

Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals announced ... Shares of Moderna gained after a couple of SEC filings showed that two ...